- Rakovina Therapeutics press release (RKV:CA): Q1 GAAP EPS of -$0.08
- Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025.
- General and administrative (G&A) expenses of $443,986, down from $1,224,752 in Q1 2025.
- Cash and cash equivalents of $585,908 as of March 31, 2026, up from $298,758 at December 31, 2025.
- Net loss of $1,675,400 for Q1 2026, compared to a net loss of $2,179,823 in Q1 2025
Rakovina Therapeutics reports Q1 results (RKV:CA:TSXV)
